drugset / Trial / NCT02067793
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-02
- Completion
- 2015-02
Outcome
Met primary endpoint
release “In a prior single-dose Phase 2 study, apimostinel demonstrated rapid and statistically significant 24-hour antidepressant effects that lasted up to seven days and was well-tolerated.” syndeio.bio ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apimostinel | Protein / enzyme biologic | 1 mg | Intravenous |
| Subject | Apimostinel | Protein / enzyme biologic | 5 mg | Intravenous |
| Subject | Apimostinel | Protein / enzyme biologic | 10 mg | Intravenous |